Analysis Of Clinical Efficacy And Safety Of Hypothermia Combined With Phenobarbital Drugs In The Treatment Of Neonatal Hypoxic-Ischemic Encephalopathy

Objective: To study the clinical efficacy and safety of hypothermia combined with phenobarbital drugs in the treatment of neonatal hypoxic-ischemic encephalopathy (HIE). Methods: A total of 100 children diagnosed with HIE in our hospital from December 2016 to November 2019 were enrolled and divided into the control group and the observation group according to different treatment methods. The control group (n=49) was treated with phenobarbital, while the observation group (n=51) received the treatment of phenobarbital combined with hypothermia. The clinical efficacy, CK, CK-MB, BUN, SCr, LDH, ALT, AST, MDI, PDI and NBNA scores were observed and compared between the two groups. Results: The time of normal consciousness, muscle tone and original recovery in the observation group were significantly shorter than those of the control group (P<0.05). The effective rate of patients with mild, moderate and severe illness in the control group was 73.34%, 73.34%, and 86.67%, respectively, while that of the observation group was 100%, 90.00% and 93.34% (P<0.05). There was no statistically significant difference in each indicator before treatment in the two groups, including CK, CK-MB, BUN, SCr, LDH, ALT and AST. After treatment, the levels of CK, CK-MB, BUN, SCr, LDH, ALT, and AST in the observation group were significantly lower than those in the control group (P<0.05). PDI evaluation and MDI index of the observation group were significantly higher than those of the control group (P<0.05). NBNA score of the observation group after treatment was significantly higher than that of the control group (P<0.05). Conclusion: The phenobarbital combined with hypothermia in the treatment of HIE can effectively recover the neurological damage and improve the therapeutic effect, which is worthy of clinical application.